Dynavax Technologies Corporation (DVAX) stock is up 7.32% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With DVAX Stock Today?
Dynavax Technologies Corporation (DVAX) stock is trading at $10.70 as of 1:14 PM on Thursday, Apr 15, an increase of $0.56, or 5.52% from the previous closing price of $10.14. The stock has traded between $10.21 and $11.04 so far today. Volume today is low. So far 2,068,116 shares have traded compared to average volume of 2,870,650 shares.
To see InvestorsObserver's Sentiment Score for Dynavax Technologies Corporation click here.
More About Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its HEPLISAV-B product.
Click Here to get the full Stock Score Report on Dynavax Technologies Corporation (DVAX) Stock.
